Drug Manufacturers, Technology

Optimising Metered Dose Inhalers for Respiratory Disorders

By H&T Presspart

Respiratory disorders affect hundreds of millions of people worldwide, with an estimated 300 million people suffering from asthma and a further 210 million with chronic obstructive pulmonary disease (COPD).

The primary treatment of these diseases is through inhaled medication, and metered dose inhalers (MDIs) are the most widely used delivery system.

MDIs have a number of advantages over alternative systems such as nebulsers or oral therapy for respiratory diseases.

Download to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.